
NYSEHealthcareMedical - Instruments & Supplies
ข้อมูลล่าสุด
US$24.35
+US$0.45 · +1.88%
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
ราคาปิดก่อนหน้า
US$24.35
+US$0.45 · +1.88%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
ช่วงราคารายวัน
ปัจจุบัน US$24.35
ช่วง 52 สัปดาห์
ปัจจุบัน US$24.35
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
32
ราคาค่อนข้างแพง
ความเชื่อมั่น
62
เชิงบวก
ความเสี่ยง
36
ความเสี่ยงปานกลาง
โมเมนตัม
54
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
ช่วงราคารายวัน
ปัจจุบัน US$24.35
ช่วง 52 สัปดาห์
ปัจจุบัน US$24.35
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 11.24B USD | 10.64B USD | 10.36B USD | 10.06B USD | 12.15B USD |
| ต้นทุนสินค้าขาย | 7.87B USD | 6.65B USD | 6.21B USD | 6.51B USD | 7.43B USD |
| กำไรขั้นต้น | 3.38B USD | 3.98B USD | 4.15B USD | 3.55B USD | 4.72B USD |
| การวิจัยและพัฒนา | 518M USD | 590M USD | 518M USD | 450M USD | 531M USD |
| การขาย ทั่วไป และธุรการ | 2.89B USD | 2.97B USD | 2.95B USD | 3.1B USD | 2.85B USD |
| ค่าใช้จ่ายในการดำเนินงาน | 3.69B USD | 3.97B USD | 3.44B USD | 6.39B USD | 3.37B USD |
| รายได้ดอกเบี้ย | 52M USD | 67M USD | 69M USD | 19M USD | 14M USD |
| ดอกเบี้ยจ่าย | 290M USD | 408M USD | 508M USD | 413M USD | 207M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 981M USD | 997M USD | 984M USD | 1.07B USD | 867M USD |
| รายได้จากการดำเนินงาน | −308M USD | 14M USD | 707M USD | −2.85B USD | 1.35B USD |
| รายได้สุทธิ | −957M USD | −649M USD | 2.66B USD | −2.43B USD | 1.28B USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 10 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$23.60
โอกาสปรับลง 3.08%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
State Street SPDR S&P 500 ETF1557.T24.15B0.02%129.34T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI427.26M0.02%2.3T USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO356.75M0.02%1.8T USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB308.83M0.16%185.3B USD0.03%US$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP191.38M0.20%96.75B USD0.20%US$213.04+0.55%
Vanguard Morningstar Small-Cap Value ETFVBR177.44M0.26%68.2B USD0.05%US$234.43+0.22%
iShares Core S&P 500 ETFIVV164.26M0.02%892.79B USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY152.61M0.02%817.2B USD0.09%US$778.57+0.60%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน